One shot to stop HPV spread? new trial tests Vaccine's hidden power
NCT ID NCT07303751
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 2 trial tests whether a single dose of the HPV vaccine (Gardasil-9) can reduce the infectivity of high-risk HPV in women aged 18-29 who already have the virus. Researchers will compare cervical samples from vaccinated and unvaccinated women at 6 months to see if vaccine-induced antibodies neutralize the virus. If successful, it could suggest a new way to control HPV transmission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kambia Research Centre
Freetown, Sierra Leone
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nonavalent HPV vaccine (Gardasil-9)
What this could lead to
If it works, this could show that a single HPV vaccine dose reduces how easily the virus spreads, potentially lowering infection rates in communities.
What could go wrong
This is a small, early-phase trial with only 80 participants. It measures infectivity in lab samples, not actual transmission, so real-world impact is uncertain. The vaccine may not reduce infectivity as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.